Search results for "PROGNOSIS"

showing 10 items of 2052 documents

Is secondary hyperparathyroidism-related myelofibrosis a negative prognostic factor for kidney transplant outcome?

2011

Secondary hyperparathyroidism (HP) presenting with hypocalcemia and subsequent increased parathormone (PTH), is mainly identified in patients with chronic renal failure, which has been associated with variable degrees of bone marrow fibrosis. For suitable patients with end-stage renal disease (ESRD), kidney transplantation is recognized as the therapy of choice, being superior to dialysis in terms of quality of life and long-term mortality risk; in this regard interesting data show that increased time on dialysis prior to kidney transplantation is associated with decreased graft and patient survival. In our opinion an important and until now underestimated determinant of graft survival is t…

Nephrologymedicine.medical_specialtymedicine.medical_treatmentUrologySettore BIO/13 - Biologia ApplicataInternal medicinemedicineHumansMyelofibrosisKidney transplantationDialysisSettore MED/14 - NefrologiaHyperparathyroidismbusiness.industryGeneral MedicinePrognosismedicine.diseaseKidney TransplantationSurgerySettore MED/18 - Chirurgia Generalemedicine.anatomical_structurePrimary MyelofibrosisKidney Failure ChronicSecondary hyperparathyroidism myelofibrosis kidney transplant chronic renal desease hemopoietic stem cells ischemia/reperfusion damegeHyperparathyroidism SecondarySecondary hyperparathyroidismBone marrowStem cellbusinessMedical Hypotheses
researchProduct

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Tri…

2021

This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.

Neuroblastoma RAS viral oncogene homologOncologyCancer Researchgenetic riskMyeloid neoplasialeukemic cells0302 clinical medicinecytarabineclinical trials and observations:Other subheadings::/diagnosis [Other subheadings]MedicineComplete remissionazacytidineolder adultsRC254-282variantsLeukemiaAzacytidineHazard ratioleukemiaVariantsCytarabineacute:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [DISEASES]Neoplasms. Tumors. Oncology. Including cancer and carcinogensMyeloid leukemiaFludarabineLeukemiaOncology030220 oncology & carcinogenesisNGSOlder adultsLeucèmia mieloide aguda - Tractamentmyeloid neoplasiaMyelocyticmedicine.drugmedicine.medical_specialtymyelocyticcomplete remission:Otros calificadores::/diagnóstico [Otros calificadores]Subgroup analysisLeukemic cellsAcutePrognostic factorsArticle:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES]03 medical and health sciencesInternal medicineGenetic riskbusiness.industryprognostic factors:diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Odds ratio:Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]medicine.diseaseAvaluació de resultats (Assistència sanitària)CytarabinebusinessClinical trials and observations030215 immunology
researchProduct

Extrahepatic spread of hepatocellular carcinoma

2012

Hepatocellular carcinoma (HCC) is a major health problem. The treatment of HCC depends on the tumour stage and on the severity of underlying cirrhosis, however, a majority of HCC patients have advanced disease at presentation. In recent years extra-hepatic spread (ES) of HCC seems to have been observed more frequently than in the past even if few data exist in literature on prevalence, clinical presentation and prognosis of patients with HCC ES. Aim of this brief review is underline the main concerns, pitfalls and warnings in practicing with these patients. ES of HCC are not rare, and the probability of finding ES is higher in patients with advanced intra-hepatic HCC. The more frequent ES s…

NiacinamideSettore MED/12 - GastroenterologiaCarcinoma HepatocellularPhenylurea CompoundsLiver NeoplasmsCarcinomaCarcinoma; Hepatocellular; Neoplasm metastasis; sorafenibAntineoplastic AgentsHepatocellularPrognosisSettore MED/28 - Malattie OdontostomatologicheAnimalsHumansNeoplasm InvasivenesssorafenibMolecular Targeted TherapyProtein Kinase InhibitorsNeoplasm metastasi
researchProduct

Nipple-sparing mastectomy and breast reconstruction with a deep inferior epigastric perforator flap using thoracodorsal recipient vessels and a low l…

2018

Background Nipple-sparing mastectomy poses challenges in providing esthetically-pleasing immediate autologous breast reconstruction. This study was to investigate the outcomes of nipple-sparing mastectomy with breast reconstruction using free abdominal flaps between two different recipient sites. Methods Between 2010 and 2016, 79 patients who underwent nipple-sparing mastectomy with autologous breast reconstruction using thoracodorsal (TD) vessels in 30 cases or internal mammary (IM) vessels in 49 cases were investigated. Demographics, intraoperative findings, complications, and quality of life using Breast-Q questionnaire were compared between two groups. Results All flap survived. There w…

Nipple-Sparing MastectomyAdultmedicine.medical_specialtymedicine.medical_treatmentMammaplastyBreast Neoplasms030230 surgeryFree Tissue Flaps03 medical and health sciencesYoung Adult0302 clinical medicineAbdominal flapsThoracic Arteriesbreast reconstruction deep inferior epigastric perforator internal mammary vessels quality of life thoracodorsal vesselsmedicineHumansMammary ArteriesMastectomyAgedbreast reconstruction; deep inferior epigastric perforator; internal mammary vessels; quality of life; thoracodorsal vessels; Adult; Aged; Anastomosis Surgical; Breast Neoplasms; Epigastric Arteries; Female; Follow-Up Studies; Free Tissue Flaps; Humans; Mammaplasty; Mammary Arteries; Mastectomy; Middle Aged; Nipples; Organ Sparing Treatments; Perforator Flap; Prognosis; Quality of Life; Thoracic Arteries; Young Adultbusiness.industryAnastomosis SurgicalCosmesisGeneral MedicineMiddle AgedPrognosisEpigastric ArteriesSurgerymedicine.anatomical_structureOncology030220 oncology & carcinogenesisNipplesMammaplastyQuality of LifeSurgeryFemalebusinessComplicationBreast reconstructionOrgan Sparing TreatmentsPerforator FlapMastectomyArteryFollow-Up Studies
researchProduct

Novelties in COPD prognosis: Evolution of survival indexes

2015

Despite several techniques, such as non-invasive ventilation (NIV), have improved the outcome of the acute exacerbation, COPD remains affected by poor prognosis in the medium and long term. Moreover, the task of predicting prognosis remains a major challenge for respiratory physicians. In order to overcome this limitation, several indexes have been proposed to assess the COPD patient in his/her complexity. The rationale is that, by using numerical indexes physicians may improve their clinical judgment to tailor and share therapeutical choices, i.e. referring the patient for surgery or lung transplantation. On this ground, Almagro et al. recently proposed the CODEX index, as the latest evolu…

Noninvasive VentilationSurvivalPrognosiPrognostic indexesSettore MED/10 - Malattie Dell'Apparato RespiratorioPrognosismortalitySurvival RatePulmonary Disease Chronic ObstructivePrognostic indexeLung transplantationCOPD; Extracorporeal carbon dioxide removal; Lung surgery; Lung transplantation; Non-invasive ventilation (NIV); Prognosis; Prognostic indexes; SurvivalExtracorporeal carbon dioxide removalHumansCOPDNon-invasive ventilation (NIV)Lung surgery
researchProduct

Prognostic value of SOX2 expression in neuroblastoma.

2010

Oncogene ProteinsCancer ResearchN-Myc Proto-Oncogene Proteinbusiness.industrySOXB1 Transcription FactorsValue (computer science)InfantNuclear ProteinsBiologyExpression (computer science)medicine.diseasePrognosisN-Myc Proto-Oncogene ProteinNeuroblastomaText miningSOX2NeuroblastomaGeneticsCancer researchmedicineHumansbusinessGenes, chromosomescancer
researchProduct

Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant …

2020

Although liver transplantation (LT) is the best treatment for patients with localized hepatocellular carcinoma (HCC), recurrence occurs in 6%-18% of patients. Several factors, particularly morphological criteria combined with dynamic parameters, known before LT modify this risk and combined in prediction models may be used to stratify patients at need of variable surveillance strategies. Additional variables though likely explain differences in recurrence rates in patients with the same pre-LT HCC status. One of these variables is possibly immunosuppression (IS). Once recurrence takes place, management is highly heterogenous. Within the International Liver Transplantation Society Consensus …

OncologyAblation Techniquesmedicine.medical_specialtyCarcinoma HepatocellularConsensusmedicine.medical_treatmentConsensus Development Conferences as TopicMEDLINE030230 surgeryLiver transplantationMedical OncologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansIn patientGrading (tumors)Societies MedicalPostoperative CareTransplantationbusiness.industryLiver NeoplasmsConsensus conferenceImmunosuppressionChemoradiotherapy Adjuvantmedicine.diseasePrognosisUnited StatesLiver TransplantationQuality of evidenceEuropeTreatment OutcomeHepatocellular carcinomaPractice Guidelines as Topic030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial …

2010

Abstract Purpose: We examined in a prospective, randomized, international clinical trial the performance of a previously defined 30-gene predictor (DLDA-30) of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide (T/FAC) chemotherapy, and assessed if DLDA-30 also predicts increased sensitivity to FAC-only chemotherapy. We compared the pCR rates after T/FAC versus FACx6 preoperative chemotherapy. We also did an exploratory analysis to identify novel candidate genes that differentially predict response in the two treatment arms. Experimental Design: Two hundred and seventy-three patients were randomly assigned to receive eith…

OncologyAdultCancer Researchmedicine.medical_specialtyCyclophosphamidePaclitaxelmedicine.drug_classmedicine.medical_treatmentBreast NeoplasmsAntimetaboliteBiomarkers PharmacologicalArticleBreast cancerPredictive Value of TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansDoxorubicinCyclophosphamideAgedChemotherapybusiness.industryCarcinoma Ductal BreastCancerMiddle Agedmedicine.diseasePrognosisSurgeryGene Expression Regulation NeoplasticTreatment OutcomeOncologyFluorouracilDoxorubicinFemaleBreast diseaseFluorouracilbusinessmedicine.drug
researchProduct

The humoral immune system has a key prognostic impact in node-negative breast cancer.

2008

Abstract Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene expression patterns of 200 tumors of patients who were not treated by systemic therapy after surgery using a discovery approach. After performing hierarchical cluster analysis, we identified coregulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B-cell and T-cell infiltration. We calculated metagenes as a surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with…

OncologyAdultCancer Researchmedicine.medical_specialtyMultivariate analysisEstrogen receptorBreast NeoplasmsMetastasisCohort StudiesBreast cancerImmune systemInternal medicineMedicineCluster AnalysisHumansAgedCell ProliferationOligonucleotide Array Sequence AnalysisAged 80 and overbusiness.industryProportional hazards modelGene Expression ProfilingHazard ratioCarcinomaMiddle Agedmedicine.diseasePrognosisGene Expression Regulation NeoplasticOncologyNeutrophil InfiltrationLymphatic MetastasisCohortImmunologyAntibody FormationFemaleLymph NodesbusinessGenes NeoplasmCancer research
researchProduct

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

2015

Abstract Purpose: To investigate the value of the metabolic tumor response assessed with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), compared with clinicobiologic markers to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in women with triple-negative breast cancer (TNBC). Experimental Design: Fifty consecutive women with TNBC and an indication for NAC were prospectively included. Different pretreatment clinical, biologic, and pathologic biomarkers, including SBR grade, the Ki-67 proliferation index, androgen receptor expression, EGF receptor (EGFR), and cytokeratin 5/6 staining, were assessed. Tumor glucose metabolism at baseline and its chan…

OncologyAdultCancer Researchmedicine.medical_specialtyPathologyProliferation indexmedicine.medical_treatmentBiopsyTriple Negative Breast NeoplasmsBreast cancerFluorodeoxyglucose F18Internal medicineBiopsyAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansEpidermal growth factor receptorTriple-negative breast cancerNeoadjuvant therapyAgedNeoplasm StagingChemotherapymedicine.diagnostic_testbiologybusiness.industryOdds ratioMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyNeoadjuvant TherapyTumor BurdenGlucoseTreatment OutcomeOncologyROC CurveLymphatic MetastasisPositron-Emission Tomographybiology.proteinFemaleNeoplasm GradingbusinessTomography X-Ray ComputedBiomarkersClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct